Rep. Collins being reviewed by House Committee on Ethics

(WROC-TV) - The U.S. House Committee on Ethics has announced it will investigate Rep. Chris Collins.

Collins (R, NY-27) is a board member of Innate Immunotherapeutics Limited (Innate) and holds stock in the company. The congressman has been facing allegations of insider trading for the company. 

In a report issued by the Board of the Office of Congressional Ethics, an initial review of the allegations of insider trading against Collins recommends that the Committee on Ethics conduct a further review "because there is a substantial reason to believe that Representative Collins shared material nonpublic information in the purchase of Innate stock, in violation of House rules, standards of conduct, and federal law."

The full report can be read here.  



More Stories

Don't Miss

Trending Stories

Latest News

Video Center